13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001017645
Total reported value
$2.9B
$2.9B
16 檔
77.6%
As reported in its official Q3 2025 Form 13F filing, General Atlantic, L.p.'s tracked investment portfolio stood at $2.9B with 16 total positions.
General Atlantic, L.p. executed strategic sector rebalancing during Q3 2025, establishing 4 new positions while fully exiting 3 holdings and trimming 4 positions.
In terms of portfolio concentration, the top 5 core holdings (including DLO, XPEV, ALHC) accounted for 77.6% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DLO | DLocal Limited | Stock-Other | 20.00% | -7.31% | -26.99% | |
| 2 | XPEV | XPeng Inc. | Stock-Other | 14.40% | -6.73% | — | |
| 3 | ALHC | Alignment Healthcare Inc | Stock-Other | 12.72% | — | -44.79% | |
| 4 | CHYM | Chime Financial Inc-cl A | Stock-Other | 11.63% | -3.55% | — | |
| 5 | ALKT | Alkami Technology Inc | Stock-Other | 8.94% | +0.89% | +24.32% | |
| 6 | AKRO | Akero Therapeutics Inc | Stock-Other | 8.17% | — | — | |
| 7 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 7.05% | -2.50% | EXIT | |
| 8 | PHVS | Pharvaris N.V. | Stock-Other | 6.02% | -2.77% | +6.64% | |
| 9 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.47% | -0.89% | — | |
| 10 | ✓ | Stock-Other | 3.20% | -0.01% | EXIT | ||
| 11 | RPRX | Royalty Pharma plc | Stock-Healthcare | 1.59% | — | — | |
| 12 | EWCZ | European Wax Center Inc-a | Stock-Other | 1.57% | -3.53% | EXIT | |
| 13 | RSKD | Riskified Ltd. | Stock-Other | 0.75% | -0.05% | — | |
| 14 | ADAG | Adagene Inc-adr | Stock-Other | 0.23% | — | -1.14% | |
| 15 | ALMS | Alumis Inc | Stock-Other | 0.16% | — | — | |
| 16 | GROV | Grove Collaborative Holdings | Stock-Other | 0.11% | -0.04% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | 260 | Centessa Pharmaceuticals-adr | +2.4% | — | Unchanged |
| 2 | DLO | DLocal Limited | +2.1% | -26.99% | Trim |
| 3 | PHVS | Pharvaris N.V. | +2.1% | +6.64% | Add |
| 4 | AKRO | Akero Therapeutics Inc | +1.1% | — | Add |
| 5 | XPEV | XPeng Inc. | +0.7% | — | Trim |
| 6 | ALKT | Alkami Technology Inc | +0.4% | +24.32% | Add |
| 7 | ADAG | Adagene Inc-adr | 0% | -1.14% | Trim |
| 8 | RPRX | Royalty Pharma plc | 0% | — | Unchanged |
| 9 | GROV | Grove Collaborative Holdings | — | — | Unchanged |
| 10 | RSKD | Riskified Ltd. | -0.1% | — | Unchanged |
| 11 | EWCZ | European Wax Center Inc-a | -0.2% | — | Unchanged |
| 12 | ALHC | Alignment Healthcare Inc | -25.4% | -44.79% | Trim |
| 13 | CHYM | Chime Financial Inc-cl A | — | NEW | New buy |
| 14 | RVMD | Revolution Medicines Inc | — | NEW | New buy |
| 15 | ✓ | — | NEW | New buy | |
| 16 | IMCR | Immunocore Holdings Plc-adr | — | EXIT | Sold out |
| 17 | ✓ | Acelyrin Inc | — | EXIT | Sold out |
| 18 | ALMS | Alumis Inc | — | NEW | New buy |
| 19 | 5ZZ0 | Contextlogic Inc - A | — | EXIT | Sold out |
According to official SEC Form 13F filings, General Atlantic, L.p. reported a total U.S. public equity portfolio value of $2.9B across 16 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
CHYM
市值: $387.4M
Top Position Liquidated / Trimmed
IMCR
前期市值: $37.4M
During Q3 2025, General Atlantic, L.p.'s top holdings by market value included DLO (20.0%)、XPEV (14.4%)、ALHC (12.7%). The largest single position, DLO, represented 20.0% of total portfolio value.
In Q3 2025, General Atlantic, L.p. made 14 total portfolio adjustments, initiating 4 new buys, adding to 3 positions, trimming 4 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.